reserved.
Translocation (9;22) Is Associated With Extremely Poor Prognosis in Intensively Treated Children With Acute Lymphoblastic Leukemia
By Jonathan A. Fletcher, Elizabeth A. Lynch, Virginia M. Kimball, Mia Donnelly, Ramana Tantravahi, and Stephen E. Sallan
The prognostic implications of t(9;22)(q34;qll) were assessed at a median follow-up of 3.5 years in 434 children receiving intensive treatment for acute lymphoblastic leukemia (ALL). Four-year event-free and overall survivals were 81% and 88%. respectively, in 419 children lacking t(9;22), but were 0% and 20%. respectively, in 15 children with t(9;22) (P < .001). Poor outcome for children with t(9;22)-positive ALL was particularly notable because we have LONAL CYTOGENETIC aberrations characterize C the leukemic blast cells in virtually all children with acute lymphoblastic leukemia (ALL).' As in other acute leukemias, those aberrations belong to a variety of distinct cytogenetic categories.'.'' Several well-defined ALL cytogenetic events have known phenotypic and others have prognostic implication^.'^^ Although hypodiploidy and pseudodiploidy have been associated with poor prognosis in childhood ALLY it appears that the poorest outcome has been in children with Philadelphia (Ph) chromosome-positive The Ph chromosome, which is a chromosome 22 lacking approximately half of its long arm, was described originally in chronic myelogenous leukemia (CML)." With the advent of improved chromosomebanding techniques, Rowley14 showed that the Ph chromosome derived from a reciprocal translocation involving chromosomes 9 and 22: t(9;22)(q34;qll). It subsequently became clear that t(9;22) also characterized 5% and 20%, respectively, of pediatric and adult ALL cases.' In both CML and Ph-positive ALL, t(9;22) results in a bcr-ab1 rearrangement on the derivative chromosome 22.'5,'6 Although (9;22) translocations in different ALL and CML cases are indistinguishable cytogenetically, bcr-ab1 rearrangements are quite heterogeneous when scrutinized at the molecular level of
The various molecular configurations of bcr-abl rearrangement appear to have distinct clinical implications in CML; however, there is no evidence that particular rearrangement sites have prognostic relevance in ALL." It is clear that many chromosome 22 rearrangements in ALL, including some of those with the truncated Ph morphology, do not result from t(9;22) and do not imply bcr-ab1 rearrangement." Those alternate rearrangements, which might derive, for example, from simple terminal deletion of chromosome 22q, appear to constitute a heterogeneous group with better prognosis than the t(9;22) group. ' Recently, we reported that the major cytogenetic categories in childhood ALL appeared to lack prognostic significance when evaluated in the context of intensive therapy." Children with hypodiploid, pseudodiploid, and translocation-positive ALL fared equally well as those with diploid and hyperdiploid disease. The only cytogenetic group that appeared to fare poorly consisted of four children with t(9;22). However, the small number of cases in that group precluded meaningful statistical analysis. To define the prognostic implications of t(9;22) in intensively treated children with ALL, we evaluated treatment response and survival for all such children treated on Dana-Farber Cancer InstituteBoston Children's Hospital ALL protocols between 1981 and 1989.
MATERIALS AND METHODS
The subjects of this study were 434 children with ALL who were enrolled on three Dana-Farber Cancer InstituteBoston Children's Hospital protocols between January 1981 and December 1989, and for whom bone marrow (BM) cytogenetic analyses were attempted. (1) adding a single dose of Escherichia coli asparaginase on the first day of treatment; (2) using only 40 mg/m2 methotrexate during induction; (3) adding a second dose of doxorubicin during remission induction for high-risk patients; (4) reducing the cranial irradiation dose for high-risk patients to 2,400 cGy; (5) adding a 1-month course of high-dose methotrexate and high-dose cytosine arabinoside, immediately after remission induction, for infants and patients with white blood cell (WBC) counts greater than 100,000/ mm'; and (6) adding intrathecal cytosine arabinoside to central newous system (CNS) treatment. Protocol no. 87-01 differed from its predecessor by: (1) randomizing between one of three asparaginase preparations, E coli, Envinia, or polyethylene glycolated (PEG)-E coli, on the first day of treatment; (2) reintroducing a 436 FLETCHER ET AL low-dose (40 mplm') versus high-dose (4 g/m') methotrexate randomization, now on day 5 of therapy; and (3) decreasing CNS radiation doses to 1,800 cGy for high-risk patients and no radiation for standard-risk patients.
Cytogenetic anaZysis. BM metaphase spreads were prepared according to previously described techniques.% Metaphase preparations were usually banded with quinacrine mustard, although Giemsa-tIypsin banding was used in a minority of cases. Chromosomal abnormalities were described using the conventions proposed in the 1985 International System of Human Cytogenetic Nomenclature." Analyses were categorized as unsuccessful if clonal chromosome aberrations were not observed and fewer than 10 metaphases were karyotyped.
The Fisher exact test was used to compare WBC count and age distributions in children with and without t(9;22). Curves for event-free and overall survival were estimated using the Kaplan-Meier method.28 Notable events, which were considered in the event-free survival determinations, included failure to achieve remission, death during induction therapy, relapse, and death during remission. Both failure to achieve complete remission (CR) and death during induction therapy were considered events as of day 1. Statistical comparisons of survival were made using the two-sided logrank test." Confidence intervals were calculated using Greenwood's formula modified for extreme values of the Kaplan-Meier estimate.M
RESULTS

Statistical analysis.
BM cytogenetic analyses were successful in 363 (84%) of the attempted analyses. The leukemic blast cells in 15 (3.5%) analyses contained t(9;22) (q34;qll) ( Table 1) . Selected clinical features for the t(9;22) group are shown in Table 2 . All children with t(9;22) were treated on the highest-risk arms of their respective protocols. Only one child (patient no. 6) was offered a first-remission BM transplant (allogeneic), and this child died of transplantrelated complications 1 year after diagnosis. No child with t(9;22) had T-cell ALL or CNS disease at the time of diagnosis. Children with t(9;22) were more likely to have Double underscore distinguishes one copy of chromosome 9 from the other copy of chromosome 9; both were involved in rearrangements. high-risk (20 to 100,000) or very high-risk (>100,000) peripheral WBC counts than were children lacking t(9;22) (P = .002). Only 40% of non-t(9;22) patients had high-risk or very high-risk WBC counts, as compared with 80% of children with t(9;22) (Table 3 ). However, there was no statistically significant difference between WBC count distributions in children with t(9;22) compared with those in the highest-risk groups who lacked t(9;22) (P = .57) ( Table   3 ). There were also no statistically significant differences in risk group related age distribution between children with or without t(9;22) ( Table 3) .
Initial attempts at remission induction were unsuccessful in three children (20%) with t(9;22), whereas CRs were induced in 413 of 419 children (99%) lacking t(9;22) (P = .003). In addition, although morphologic BM evaluation indicated CR in patient no. 6, cytogenetic analyses of four successive "remission" BMs showed a low level (2% to 10%) of persistent t(9;22)-positive cells. Based on protocol criteria, this child was categorized as a complete responder ( Table 2) .
Of the 12 children with t(9;22) who attained a CR, only three remained in continuous CR (CCR) at the time of this analysis in February 1990 (Table 2) , and each of those three children had been followed for less than 2 years from time of diagnosis. The longest duration of morphologic CR in At a median follow-up of 3.5 years, 4-year event-free survivals (95% CI) for those children with and without t(9;22), were 0% and 81.1% (76.7%, 85.6%), respectively (P < .OOl) (Fig 1) . Four-year overall survivals (95% CI) for the same groups were 20.4% (3.3%, 47.7%) and 88.2% (84.6%, 91.8%), respectively (P < .001).
In addition to the 15 children with t(9;22), 132 other children in this series were treated on the highest-risk arms of their respective protocols. Four-year event-free (Fig 1) and overall survivals (95% CI) for the highest-risk children who lacked t(9;22) were 76.6% (69%, 84.1 %) and 83.3% (77.2%, 90.3%), respectively. These survival results were significantly better than those in children with t(9;22)-positive disease (P < .OOl).
-7,t(9;22).
Comparison of t(9;22) and other "high-risk" groups.
DISCUSSION
In this study we assessed the prognostic implications of t(9;22) in intensively treated children with ALL. In ALL, the t(9;22) category, designating a specific cytogenetic event, is a subgroup of the Ph chromosome category. Ph chromosome "variants" that do not result from t(9;22) have been shown to lack bcr-ab1 rearrangement and have not been associated with poor prognosis.93u Accordingly, the survival comparisons in this study were between cases with and without t(9;22). Fifteen children with t(9;22) were characterized by extremely low event-free and overall survival rates compared with 419 children who lacked t(9;22). Those survival differences were striking given that the t(9;22) cases received the most intensive treatment options in their respective protocols. In contrast, we have reported previously that several poor-prognosis cytogenetic categories, including hypodiploidy and pseudodiploidy, appeared to have little survival relevance when evaluated in the context of similarly intensive treatment.u
As in previous reports, we noted t(9;22) to be associated with higher WBC count at diagnosis. However, unlike Ribeiro et al,9 we did not observe an increased frequency of CNS disease in children with t(9;22). It is possible that higher WBC count at diagnosis, a known adverse risk factor in childhood ALL, contributed to the poor prognosis of t (9;22) . Although there were too few cases to permit multivariate analysis of potential prognosticators, extremely short survivals in the t(9;22) group were also seen in those with low-presenting WBC counts ( Table 2) . Furthermore, children who lacked t(9;22), but who were in the highest-risk groups based on presenting ages and WBC counts, did not fare poorly in this series. Therefore, it is likely that t(9;22) had independent prognostic value.
One of our cases (patient no. 6) had a low level of t(9;22)-positive cells despite morphologic evidence of CR. Allogeneic BM transplantation was followed by both morphologic and cytogenetic CR, but the child died subsequently of transplant-related complications. Molecular studies were not performed in that case, and it is unclear whether the residual pretransplant t(9;22)-positive cells reflected de novo ALL with stem-cell involvement or, alternately, acute lymphoid transformation in adult-type CML. Another child (patient no. 5) had an unusually prolonged course in which recurrence of t(9;22)-positive cells was first noted 3 months after completion of therapy; t(9;22)-positive cells then persisted, despite histologic evidence of CCR, for 3 years. At that time, frank histologic relapse was accompanied by new observation of monosomy 7 in addition to the t(9;22). This unusual case suggests that additional genetic events, some of which might be beyond the cytogenetic level of resolution, might be needed to induce the aggressive phenotype seen in most cases of t(9;22)-positive ALL. Intensive chemotherapy in such cases might preferentially eliminate more evolved, mitotically active components of the leukemic process, leaving a slowly proliferating residual population of leukemic cells that contain only the basic t(9;22). Subsequent additional mutations in these residual populations might then restore the fully aggressive malignant phenotype.
The short survival for t(9;22)-positive children occurred despite an intensive therapeutic approach which has resulted in excellent event-free survival for other high-risk patient^.^.'^ Accordingly, it is appropriate to consider more intensive and experimental treatment approaches for children in the t(9;22) group. At present, we recommend the option of allogeneic BM transplantation for all children with t(9;22)-positive ALL who achieve a CR.31-33 Although a fully HLA-matched related donor might be preferable, HLA-matched unrelated donors or partially matched related donors should also be considered; the graft-versushost disease associated with these approaches would appear to be justified given the dismal survival after use only. 
